Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 421

Sort by

Sort Order Select

Journal Articles

Addition of obinutuzumab after one year of combined acalabrutinib and venetoclax is safer and effective than early obinutuzumab in a randomized Phase II trial for treatment naïve CLL

Blood (2025) 146 (Supplement 1): 681.

https://doi.org/10.1182/blood-2025-681

Published: 2025

Journal Articles

Time-limited pirtobrutinib, venetoclax, and obinutuzumab combination in first-line chronic lymphocytic leukemia

Blood (2025) 146 (Supplement 1): 680.

https://doi.org/10.1182/blood-2025-680

Published: 2025

Journal Articles

The addition of inotuzumab ozogamicin to frontline hyper-CVAD and sequential blinatumomab leads to durable survival outcomes in adults with newly diagnosed B-cell acute lymphoblastic leukemia: Four-year follow-up of a phase 2 study

Hannah Goulart, Hagop Kantarjian, Nitin Jain, Rita Khouri, Tapan Kadia, Courtney DiNardo, Naval Daver, Naveen Pemmaraju, Alessandra Ferrajoli, Alex Bataller, Fadi Haddad, Jayastu Senapati, Guillermo Garcia-Manero, Rebecca Garris, Farhad Ravandi, Nicholas Short, Elias Jabbour

Blood (2025) 146 (Supplement 1): 1567.

https://doi.org/10.1182/blood-2025-1567

Published: 2025

Journal Articles

Combination of CPX-351 and gemtuzumab ozogamicin (GO) in relapsed/refractory (R/R) Acute Myeloid Leukemia and post-hypomethylating agent (HMA) failure high-risk myelodysplastic syndrome (HR-MDS)

Farah Al Haj, Mina Abdelmalek, Jayastu Senapati, Guillermo Montalban-Bravo, Stefan Faderl, William D. Marrero, Nicholas Short, Naval Daver, Courtney DiNardo, Lucia Masarova, Alessandra Ferrajoli, Elias Jabbour, Gautam Borthakur, Guillermo Garcia-Manero, Michael Andreeff, Tapan Kadia, Farhad Ravandi, Yesid Alvarado Valero

Blood (2025) 146 (Supplement 1): 1688.

https://doi.org/10.1182/blood-2025-1688

Published: 2025

Journal Articles

Pirtobrutinib, venetoclax, and obinutuzumab for patients with richter transformation: A phase 2 trial

Blood (2025) 146 (Supplement 1): 89.

https://doi.org/10.1182/blood-2025-89

Published: 2025

Journal Articles

Other cancers in patients with chronic lymphocytic leukemia/SMALL lymphocytic lymphoma

Helen Ma, Kari Rabe, Edward Ratner, Samuel Kosydar, Roberta Santos Azevedo, Pankaj Gupta, Susan O'Brien, Paul Hampel, Lindsey Roeker, Yucai Wang, Susan Slager, Sameer Parikh, Alessandra Ferrajoli

Blood (2025) 146 (Supplement 1): 4529.

https://doi.org/10.1182/blood-2025-4529

Published: 2025

Journal Articles

Venetoclax-based therapies in patients with Relapsed/Refractory T-cell prolymphocytic leukemia

Roberta S. Azevedo, Caitlin Rausch, Alexis Geppner, Francisco Vega, Deepa Sampath, Alessandra Ferrajoli, Kelly Chien, Elias Jabbour, Danielle Hammond, Nicholas Short, Koichi Takahashi, Nitin Jain, Jan Burger, Gautam Borthakur, William Wierda, Chitra Hosing, Farhad Ravandi, Tapan Kadia

Blood (2025) 146 (Supplement 1): 3653.

https://doi.org/10.1182/blood-2025-3653

Published: 2025

Journal Articles

Incidence of cardiac-related deaths among patients aged ≥65 years with B-cell malignancies treated with ibrutinib

Ryan Jacobs, Alessandra Ferrajoli, Xiaoliang Wang, Qianhong Fu, Andrea Barthel, Neil Lamarre, Yajin Zhao, Jeffrey Anderson, Derrick van Beuge, Ayad K. Ali, Michael Fradley

Blood (2025) 146 (Supplement 1): 8066.

https://doi.org/10.1182/blood-2025-8066

Published: 2025

Journal Articles

Longitudinal trends in vaccination and cancer screening engagement among patients with chronic lymphocytic leukemia: A prospective cohort study and quality improvement initiative (2019–2025)

Vanthana Bharathi, Kristofer Jennings, Jackie Broadway-Duren, Mahesh Swaminathan, Nitin Jain, William Wierda, Jan Burger, Dervy Salcedo, Stephanie Zelaya, Margaret Pace, Mariela Sivina, Alessandra Ferrajoli

Blood (2025) 146 (Supplement 1): 517.

https://doi.org/10.1182/blood-2025-517

Published: 2025

Journal Articles

Target dose delivery comparison: Ibrutinib + venetoclax vs. acalabrutinib + venetoclax in treatment-Naïve CLL patients in prospective clinical trials

Mahesh Swaminathan, Nitin Jain, Alexandra Lovell, Ashley Dinh, Alessandra Ferrajoli, Jan Burger, Musa Yilmaz, Tapan Kadia, Lucia Masarova, Yesid Alvarado Valero, Prithviraj Bose, Farhad Ravandi, Koji Sasaki, Wei Qiao, Zhouxuan Li, Naveen Garg, Michael Keating, William Wierda

Blood (2025) 146 (Supplement 1): 5687.

https://doi.org/10.1182/blood-2025-5687

Published: 2025

Journal Articles

Long progression-free survival with venetoclax consolidation in patients with high-risk chronic lymphocytic leukemia treated with ibrutinib.

Vishrut Shah, Philip Thompson, Grace Nie, Nitin Jain, Blanche Anderson, Tapan Kadia, Prithviraj Bose, Naveen Pemmaraju, Nicholas Short, Sa Wang, Jeffrey Jorgensen, Christine Peterson, William Wierda, Alessandra Ferrajoli

Blood (2025) 146 (Supplement 1): 5686.

https://doi.org/10.1182/blood-2025-5686

Published: 2025

Journal Articles

Venetoclax initiation monitoring and interventions after acalabrutinib lead-in for chronic lymphocytic leukemia

Alexandra Lovell, Emily Lee, Mikaela McCabe, Nitin Jain, Alessandra Ferrajoli, Mahesh Swaminathan, Jan Burger, William Wierda

Blood (2025) 146 (Supplement 1): 5685.

https://doi.org/10.1182/blood-2025-5685

Published: 2025

Journal Articles

Acalabrutinib-obinutuzumab improves survival vs chemoimmunotherapy in treatment-naive CLL in the 6-year follow-up of ELEVATE-TN

Blood (2025) 146 (11): 1276–1285.

https://doi.org/10.1182/blood.2024024476

Published: 2025

Includes: Supplemental data

Journal Articles

Sustained benefit of zanubrutinib vs ibrutinib in patients with R/R CLL/SLL: final comparative analysis of ALPINE

Blood (2024) 144 (26): 2706–2717.

https://doi.org/10.1182/blood.2024024667

Published: 2024

Includes: Supplemental data

Journal Articles

Deuterated water labeling in ibrutinib-treated patients with CLL: leukemia cell kinetics correlate with IGHV , ZAP-70, and MRD

Ekaterina Kim, Shih-Shih Chen, Mariela Sivina, Hyunsoo Hwang, Xuelin Huang, Alessandra Ferrajoli, Nitin Jain, William G. Wierda, Dominik Wodarz, Nicholas Chiorazzi, Jan A. Burger

Blood (2024) 144 (25): 2678–2681.

https://doi.org/10.1182/blood.2024025683

Published: 2024

Includes: Supplemental data

Journal Articles

Comprehensive Characteristics and Outcomes of Myeloid Neoplasms Following Chimeric Antigen Receptor T-Cell Therapy for Other Hematologic Malignancies

Blood (2024) 144 (Supplement 1): 1837.

https://doi.org/10.1182/blood-2024-206801

Published: 2024

Journal Articles

Combination of CPX-351 and Gemtuzumab Ozogamicin (GO) in Relapsed Refractory (R/R) Acute Myeloid Leukemia and Post Hypomethylating Agent (HMA) Failure High-Risk Myelodysplastic Syndrome (HR-MDS)

Blood (2024) 144 (Supplement 1): 2903.

https://doi.org/10.1182/blood-2024-207962

Published: 2024

Journal Articles

Early Obinutuzumab Significantly Increases Bone Marrow Undetectable MRD (10 -4 sensitivity) (uMRD4) Rate When Combined with Acalabrutinib and Venetoclax in a Randomized Phase II Trial for Treatment Naïve CLL

Blood (2024) 144 (Supplement 1): 1855.

https://doi.org/10.1182/blood-2024-211110

Published: 2024

Journal Articles

Time-Limited Therapy with Zanubrutinib Plus Rituximab in Patients with Treatment-Naïve Chronic Lymphocytic Leukemia: Early Results of an Ongoing Phase II Trial

Jan A. Burger, Ekaterina Kim, Gitanjali Jayachandran, Thomas Mathew, Koji Sasaki, Yesid Alvarado Valero, Danielle Hammond, Fadi G. Haddad, William G. Wierda, Alessandra Ferrajoli

Blood (2024) 144 (Supplement 1): 4631.

https://doi.org/10.1182/blood-2024-198701

Published: 2024

Journal Articles

Combined Pirtobrutinib, Venetoclax, and Obinutuzumab As First-Line Treatment of Patients with Chronic Lymphocytic Leukemia (CLL)

Blood (2024) 144 (Supplement 1): 1011.

https://doi.org/10.1182/blood-2024-211454

Published: 2024

Update search

NARROW

Publications

Format

Subjects

Article Type

Topics

Date

Availability

Addition of obinutuzumab after one year of combined acalabrutinib and venetoclax is safer and effective than early obinutuzumab in a randomized Phase II trial for treatment naïve CLL

Time-limited pirtobrutinib, venetoclax, and obinutuzumab combination in first-line chronic lymphocytic leukemia

The addition of inotuzumab ozogamicin to frontline hyper-CVAD and sequential blinatumomab leads to durable survival outcomes in adults with newly diagnosed B-cell acute lymphoblastic leukemia: Four-year follow-up of a phase 2 study

Combination of CPX-351 and gemtuzumab ozogamicin (GO) in relapsed/refractory (R/R) Acute Myeloid Leukemia and post-hypomethylating agent (HMA) failure high-risk myelodysplastic syndrome (HR-MDS)

Pirtobrutinib, venetoclax, and obinutuzumab for patients with richter transformation: A phase 2 trial

Other cancers in patients with chronic lymphocytic leukemia/SMALL lymphocytic lymphoma

Venetoclax-based therapies in patients with Relapsed/Refractory T-cell prolymphocytic leukemia

Incidence of cardiac-related deaths among patients aged ≥65 years with B-cell malignancies treated with ibrutinib

Longitudinal trends in vaccination and cancer screening engagement among patients with chronic lymphocytic leukemia: A prospective cohort study and quality improvement initiative (2019–2025)

Target dose delivery comparison: Ibrutinib + venetoclax vs. acalabrutinib + venetoclax in treatment-Naïve CLL patients in prospective clinical trials

Long progression-free survival with venetoclax consolidation in patients with high-risk chronic lymphocytic leukemia treated with ibrutinib.

Venetoclax initiation monitoring and interventions after acalabrutinib lead-in for chronic lymphocytic leukemia

Acalabrutinib-obinutuzumab improves survival vs chemoimmunotherapy in treatment-naive CLL in the 6-year follow-up of ELEVATE-TN

Sustained benefit of zanubrutinib vs ibrutinib in patients with R/R CLL/SLL: final comparative analysis of ALPINE

Deuterated water labeling in ibrutinib-treated patients with CLL: leukemia cell kinetics correlate with IGHV , ZAP-70, and MRD

Comprehensive Characteristics and Outcomes of Myeloid Neoplasms Following Chimeric Antigen Receptor T-Cell Therapy for Other Hematologic Malignancies

Combination of CPX-351 and Gemtuzumab Ozogamicin (GO) in Relapsed Refractory (R/R) Acute Myeloid Leukemia and Post Hypomethylating Agent (HMA) Failure High-Risk Myelodysplastic Syndrome (HR-MDS)

Early Obinutuzumab Significantly Increases Bone Marrow Undetectable MRD (10 -4 sensitivity) (uMRD4) Rate When Combined with Acalabrutinib and Venetoclax in a Randomized Phase II Trial for Treatment Naïve CLL

Time-Limited Therapy with Zanubrutinib Plus Rituximab in Patients with Treatment-Naïve Chronic Lymphocytic Leukemia: Early Results of an Ongoing Phase II Trial

Combined Pirtobrutinib, Venetoclax, and Obinutuzumab As First-Line Treatment of Patients with Chronic Lymphocytic Leukemia (CLL)

Email alerts

ASH Publications

American Society of Hematology

Update search

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only